Do you need personalized information about ADHD treatments?
Evimatic® is your personal analyzer of scientific evidence on therapeutics. Currently, Evimatic® provides personalized and updated information on the efficacy and safety of treatments for ADHD, with the intention of progressively expanding its scope to other diseases.
Do you need personalized information about ADHD treatments?
Evimatic® is your personal analyzer of scientific evidence on therapeutics. Currently, Evimatic® provides personalized and updated information on the efficacy and safety of treatments for ADHD, with the intention of progressively expanding its scope to other diseases.
What is Evimatic®?
Evimatic® is an AI tool that generates new content and knowledge about ADHD treatments based on user-submitted questions.
Evimatic® is the first AI-based information system that offers users:
- An analysis of scientific evidence
- An evaluation of the quality of scientific evidence
- A study of the benefit-risk relationship of pharmacological and non-pharmacological treatments
- A ranking of treatments based on the parameters selected by the user
Who is Evimatic® for?
Evimatic® is designed for anyone seeking updated and personalized information on the efficacy, safety, and, potentially, the benefit-risk relationship of ADHD treatments.
These users may include, among others:
- Clinicians treating individuals with ADHD
- Individuals with ADHD or their family members
- Developers of clinical practice guidelines for ADHD
- Researchers in the field of ADHD
- Health technology assessors
- Employees of companies with an interest in ADHD
- Health journalists.
Validation of Evimatic technology®
The successive technological developments leading to Evimatic® have received two quality seals from ITEMAS , the platform for promotion and innovation of the Instituto de Salud Carlos III.
Validation of Evimatic technology®
The successive technological developments leading to Evimatic® have received two quality seals from ITEMAS , the platform for promotion and innovation of the Instituto de Salud Carlos III.
Sponsors and collaborators
